Bloodless medicine: current strategies and emerging treatment paradigms

Transfusion

Volumn 56, Issue 10, 2016, Pages 2637-2647

  Resar, Linda M S ^a,b   Wick, Elizabeth C ^a   Almasri, Talal Nael ^a   Dackiw, Elizabeth A ^a   Ness, Paul M ^a,c   Frank, Steven M ^a  

^a the ^*  (United States)

^b Institute for Cell Engineering   (United States)

^c DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALBUMIN; ANTIANEMIC AGENT; CELECOXIB; CYANOCOBALAMIN; ERYTHROPOIETIN; FERRITIN; FOLIC ACID; IRON; POLYMERIZED HEMOGLOBIN; PRASUGREL; TRANSFERRIN; WARFARIN;

ANEMIA; ATRIAL FIBRILLATION; BLEEDING; BLEEDING TENDENCY; BLOODLESS CARE; HUMAN; IRON DEFICIENCY; PERINATAL PERIOD; PHLEBOTOMY; POSTOPERATIVE CARE; PRIORITY JOURNAL; REVIEW; ALLOTRANSPLANTATION; BLOOD TRANSFUSION; PROCEDURES; UTILIZATION;

ANEMIA; BLOOD TRANSFUSION; BLOODLESS MEDICAL AND SURGICAL PROCEDURES; HUMANS; TRANSPLANTATION, HOMOLOGOUS;

EID: 84979760376     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/trf.13736     Document Type: Review

References (65)

1. Farrugia A. Falsification or paradigm shift? Toward a revision of the common sense of transfusion. Transfusion 2011;51:216–24.
2. Vamvakas EC. Reasons for moving toward a patient-centric paradigm of clinical transfusion medicine practice. Transfusion 2013;53:888–901.
3. Waters JH, Ness PM. Patient blood management: a growing challenge and opportunity. Transfusion 2011;51:902–3.
4. Bhaskar B, Jack RK, Mullany D, et al. Comparison of outcome in Jehovah's Witness patients in cardiac surgery: an Australian experience. Heart Lung Circ 2010;19:655–9.
5. Frank SM, Wick EC, Dezern AE, et al. Risk-adjusted clinical outcomes in patients enrolled in a bloodless program. Transfusion 2014;54:2668–77.
6. Guinn NR, Roberson RS, White W, et al. Costs and outcomes after cardiac surgery in patients refusing transfusion compared with those who do not: a case-matched study. Transfusion 2015;55:2791–8.
7. Jassar AS, Ford PA, Haber HL, et al. Cardiac surgery in Jehovah's Witness patients: ten-year experience. Ann Thorac Surg 2012;93:19–25.
8. McCartney S, Guinn N, Roberson R, et al. Jehovah's Witnesses and cardiac surgery: a single institution's experience. Transfusion 2014;54:2745–52.
9. Resar LM, Frank SM. Bloodless medicine: what to do when you can't transfuse. Hematology Am Soc Hematol Educ Program 2014;2014:553–8.
10. Bodnaruk ZM, Wong CJ, Thomas MJ. Meeting the clinical challenge of care for Jehovah's Witnesses. Transfus Med Rev 2004;18:105–16.
11. Watch Tower Bible and Tract Society of New York. Yearbook of Jehovah's Witnesses. Brooklyn (NY): Watch Tower Bible and Tract Society of New York; 2015. p. 176–86.
12. Angouras DC. Jehovah's Witnesses may not have identical outcomes with nontransfused non-witnesses after cardiac surgery. JAMA Intern Med 2013;173:248–9.
13. Vaislic CD, Dalibon N, Ponzio O, et al. Outcomes in cardiac surgery in 500 consecutive Jehovah's Witness patients: 21 year experience. J Cardiothorac Surg 2012;7:95.
14. Pattakos G, Koch CG, Brizzio ME, et al. Outcome of patients who refuse transfusion after cardiac surgery: a natural experiment with severe blood conservation. Arch Intern Med 2012;172:1154–60.
15. Emmert MY, Salzberg SP, Theusinger OM, et al. How good patient blood management leads to excellent outcomes in Jehovah's Witness patients undergoing cardiac surgery. Interact Cardiovasc Thorac Surg 2011;12:183–8.
16. Juraszek A, Dziodzio T, Roedler S, et al. Results of open heart surgery in Jehovah's Witnesses patients. J Cardiovasc Surg (Torino) 2009;50:247–50.
17. Casati V, D'Angelo A, Barbato L, et al. Perioperative management of four anaemic female Jehovah's Witnesses undergoing urgent complex cardiac surgery. Br J Anaesth 2007;99:349–52.
18. Reyes G, Nuche JM, Sarraj A, et al. Bloodless cardiac surgery in Jehovah's Witnesses: outcomes compared with a control group. Rev Esp Cardiol 2007;60:727–31.
19. Stamou SC, White T, Barnett S, et al. Comparisons of cardiac surgery outcomes in Jehovah's versus non-Jehovah's Witnesses. Am J Cardiol 2006;98:1223–5.
20. Helm RE, Rosengart TK, Gomez M, et al. Comprehensive multimodality blood conservation: 100 consecutive CABG operations without transfusion. Ann Thorac Surg 1998;65:125–36.
21. Koch CG, Li L, Duncan AI, et al. Morbidity and mortality risk associated with red blood cell and blood-component transfusion in isolated coronary artery bypass grafting. Crit Care Med 2006;34:1608–16.
22. Shander A, Knight K, Thurer R, et al. Prevalence and outcomes of anemia in surgery: a systematic review of the literature. Am J Med 2004;116(Suppl7A):58S–69S.
23. Goodnough LT. Blood management: transfusion medicine comes of age. Lancet 2013;381:1791–2.
24. Shander A, Javidroozi M, Goodnough LT. Anemia screening in elective surgery: definition, significance and patients' interests. Anesth Analg 2006;103:778–9.
25. Lillicrap D. von Willebrand disease: advances in pathogenetic understanding, diagnosis, and therapy. Blood 2013;122:3735–40.
26. Chant C, Wilson G, Friedrich JO. Anemia, transfusion, and phlebotomy practices in critically ill patients with prolonged ICU length of stay: a cohort study [serial online]. Crit Care 2006;10:R140.
27. Koch CG, Reineks EZ, Tang AS, et al. Contemporary bloodletting in cardiac surgical care. Ann Thorac Surg 2015;99:779–84.
28. Partovi S, Bruckner BA, Staub D, et al. Bloodless lung transplantation in Jehovah's Witnesses: impact on perioperative parameters and outcome compared with a matched control group. Transplant Proc 2013;45:335–41.
29. Pompei E, Tursi V, Guzzi G, et al. Mid-term clinical outcomes in cardiac surgery of Jehovah's Witnesses. J Cardiovasc Med 2010;11:170–4.
30. Joseph SA Jr, Berekashvili K, Mariller MM, et al. Blood conservation techniques in spinal deformity surgery: a retrospective review of patients refusing blood transfusion. Spine (Phila Pa 1976) 2008;33:2310–5.
31. Jabbour N, Gagandeep S, Mateo R, et al. Live donor liver transplantation without blood products: strategies developed for Jehovah's Witnesses offer broad application. Ann Surg 2004;240:350–7.
32. Suess S, Suess O, Brock M. Neurosurgical procedures in Jehovah's Witnesses: an increased risk? Neurosurgery 2001;49:266–72.
33. Chikada M, Furuse A, Kotsuka Y, et al. Open-heart surgery in Jehovah's Witness patients. Cardiovasc Surg 1996;4:311–4.
34. Rosengart TK, Helm RE, Klemperer J, et al. Combined aprotinin and erythropoietin use for blood conservation: results with Jehovah's Witnesses. Ann Thorac Surg 1994;58:1397–403.
35. Kaufman DB, Sutherland DE, Fryd DS, et al. A single-center experience of renal transplantation in thirteen Jehovah's Witnesses. Transplantation 1988;45:1045–9.
36. Singla AK, Lapinski RH, Berkowitz RL, et al. Are women who are Jehovah's Witnesses at risk of maternal death? Am J Obstet Gynecol 2001;185:893–5.
37. Koch TA, Myers J, Goodnough LT. Intravenous iron therapy in patients with iron deficiency anemia: dosing considerations. Anemia 2015;2015:763576.
38. Auerbach M, Pappadakis JA, Bahrain H, et al. Safety and efficacy of rapidly administered (one hour) one gram of low molecular weight iron dextran (INFeD) for the treatment of iron deficient anemia. Am J Hematol 2011;86:860–2.
39. Auerbach M, Al Talib K. Low-molecular weight iron dextran and iron sucrose have similar comparative safety profiles in chronic kidney disease. Kidney Int 2008;73:528–30.
40. Goodnough LT, Marcus RE. Erythropoiesis in patients stimulated with erythropoietin: the relevance of storage iron. Vox Sang 1998;75:128–33.
41. Casadevall N, Nataf J, Viron B, et al. Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N Engl J Med 2002;346:469–75.
42. Stroupe KT, Tarlov E, Lee TA, et al. Hemoglobin levels triggering erythropoiesis-stimulating agent therapy in patients with cancer: the shift after United States Food and Drug Administration policy changes. Pharmacotherapy 2012;32:988–97.
43. Palmer SC, Navaneethan SD, Craig JC, et al. Meta-analysis: erythropoiesis-stimulating agents in patients with chronic kidney disease. Ann Intern Med 2010;153:23–33.
44. Douketis JD, Spyropoulos AC, Spencer FA, et al. Perioperative management of antithrombotic therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012;141:e326S–50S.
45. Waters JH, Yazer M, Chen YF, et al. Blood salvage and cancer surgery: a meta-analysis of available studies. Transfusion 2012;52:2167–73.
46. Waters JH, Donnenberg AD. Blood salvage and cancer surgery: should we do it? Transfusion 2009;49:2016–8.
47. Waters JH, Tuohy MJ, Hobson DF, et al. Bacterial reduction by cell salvage washing and leukocyte depletion filtration. Anesthesiology 2003;99:652–5.
48. Frank SM, Wasey JO, Dwyer IM, Gokaslan ZL, Ness PM, Kebaish KM. Radiofrequency bipolar hemostatic sealer reduces blood loss, transfusion requirements, and cost for patients undergoing multilevel spinal fusion surgery: a case control study [serial online]. J Orthop Surg Res 2014;9:50.
49. Grant MC, Resar LM, Frank SM. The efficacy and utility of acute normovolemic hemodilution. Anesth Analg 2015;121:1412–4.
50. Shander A, Rijhwani TS. Acute normovolemic hemodilution. Transfusion 2004;44:26S–34S.
51. Ozier Y, Bellamy L. Pharmacological agents: antifibrinolytics and desmopressin. Best Pract Res Clin Anaesthesiol 2010;24:107–19.
52. Stone AB, Grant MC, Pio Roda C, et al. Implementation costs of an enhanced recovery after surgery program in the United States: a financial model and sensitivity analysis based on experiences at a quaternary academic medical center. J Am Coll Surg 2016;222:219–25.
53. Grant MC, Whitman GJ, Savage WJ, et al. Clinical predictors of postoperative hemoglobin drift. Transfusion 2014;54:1460–8.
54. Mackenzie CF, Moon-Massat PF, Shander A, et al. When blood is not an option: factors affecting survival after the use of a hemoglobin-based oxygen carrier in 54 patients with life-threatening anemia. Anesth Analg 2010;110:685–93.
55. Serruys PW, Vranckx P, Slagboom T, et al. Haemodynamic effects, safety, and tolerability of haemoglobin-based oxygen carrier-201 in patients undergoing PCI for CAD. EuroIntervention 2008;3:600–9.
56. Abuchowski A. Pegylated bovine carboxyhemoglobin (SANGUINATE): results of clinical safety testing and use in patients. Adv Exp Med Biol 2016;876:461–7.
57. Posluszny JA Jr, Napolitano LM. How do we treat life-threatening anemia in a Jehovah's Witness patient? Transfusion 2014;54:3026–34.
58. Meneghini L, Zadra N, Aneloni V, Metrangolo S, Faggin R, Guisti F. Erythropoietin therapy and acute preoperative normovolaemic haemodilution in infants undergoing craniosynostosis surgery. Pediatr Anaesth 2003;13:392–6.
59. Fearon JA, Weinthal J. The use of recombinant erythropoietin in the reduction of blood transfusion rates in craniosynostosis repair in infants and children. Plast Reconstr Surg 2002;109:2190–6.
60. Helfaer MA, Carson BS, James CS, et al. Increased hematocrit and decreased transfusion requirements in children given erythropoietin before undergoing craniofacial surgery. J Neurosurg 1998;88:704–8.
61. Vitale MG, Privitera DM, Matsumoto H, et al. Efficacy of preoperative erythropoietin administration in pediatric neuromuscular scoliosis patients. Spine 2007;32:2662–7.
62. Vitale MG, Roye BD, Ruchelsman DE, Rove DP Jr. Preoperative use of recombinant human erythropoietin in pediatric orthopedics: a decision model for long-term outcomes. Spine J 2007;7:292–300.
63. Shermock KM, Horn E, Rice TL. Erythropoietic agents for anemia of critical illness. Am J Health Syst Pharm 2008;65:540–6.
64. Lindholm J, Palmer K, Frenckner B. Long-term ECMO treatment in Jehovah's Witness patient without transfusions. Perfusion 2012;27:332–4.
65. Lanzkron S, Moliterno AR, Norris EJ, et al. Polymerized human Hb use in acute chest syndrome: a case report. Transfusion 2002;42:1422–7.